Starling Oncology, Inc. (STLNW) Net margin 2020–2025
Starling Oncology, Inc. (STLNW) net profit margin by fiscal year — reported net income divided by reported revenue.
-12.1%FY2025 · since FY2020: -7.6% → -12.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -12.1% | +4.4 pp |
| FY2024 | -16.4% | +9.2 pp |
| FY2023 | -25.6% | -25.7 pp |
| FY2022 | 0.1% | +5.4 pp |
| FY2021 | -5.4% | +2.3 pp |
| FY2020 | -7.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More STLNW financial trends
STLNW RevenueSTLNW Net incomeSTLNW Gross profitSTLNW Gross marginSTLNW Operating incomeSTLNW Operating marginSTLNW Operating cash flowSTLNW Free cash flowSTLNW Capital expendituresSTLNW Return on equitySTLNW Stock buybacksSTLNW Dividends paidSTLNW Total assetsSTLNW Total liabilitiesSTLNW Shareholders’ equitySTLNW overview →